{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:47:12Z","timestamp":1792392432988,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eclinm.2024.102914","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T17:41:56Z","timestamp":1731519716000},"page":"102914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6082-2263","authenticated-orcid":false,"given":"Susanne","family":"Osanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laurien van de","family":"Vliert-Bout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-1485","authenticated-orcid":false,"given":"Cristina Alvarez","family":"Gomez de Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-Paul","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-4781","authenticated-orcid":false,"given":"Jan","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-9867","authenticated-orcid":false,"given":"Sahar","family":"Barjesteh van Waalwijk van Doorn-Khosrovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eclinm.2024.102914_bib1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A\u00a0standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102914_bib2","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102914_bib3","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102914_bib4","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102914_bib5","series-title":"Patient-reported outcome measures: use in medical product development to support labeling claims - guidance for industry","year":"2009"},{"key":"10.1016\/j.eclinm.2024.102914_bib6","series-title":"Clinical trial endpoints for the approval of cancer drugs and biologics - guidance for industry","year":"2018"},{"key":"10.1016\/j.eclinm.2024.102914_bib7","series-title":"FDA in brief: FDA provides guidance on measuring patient-reported outcomes in cancer clinical trials","year":"2021"},{"key":"10.1016\/j.eclinm.2024.102914_bib8","series-title":"Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man - the use of patient-reported outcome (PRO) measures in oncology studies","year":"2016"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.annonc.2022.12.004","article-title":"Methodological and reporting standards for quality-of-life data eligible for European society for medical oncology-magnitude of clinical benefit scale (ESMO-MCBS) credit","volume":"34","author":"Oosting","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102914_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102914_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2013.10.017","article-title":"Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making","volume":"66","author":"Efficace","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eclinm.2024.102914_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11136-015-1099-z","article-title":"International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies","volume":"25","author":"Kyte","year":"2016","journal-title":"Qual Life Res"},{"issue":"18","key":"10.1016\/j.eclinm.2024.102914_bib14","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2003.12.121","article-title":"Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?","volume":"21","author":"Efficace","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdl494","article-title":"Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making","volume":"18","author":"Efficace","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102914_bib16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102914_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102914_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bju.13687","article-title":"Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","volume":"119","author":"Gilbert","year":"2017","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102914_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102914_bib21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.eururo.2020.08.023","volume":"79","author":"Boev\u00e9","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102914_bib24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume":"40","author":"Rush","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102914_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102914_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102914_bib28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102914_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"32","key":"10.1016\/j.eclinm.2024.102914_bib30","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102914_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"10024","key":"10.1016\/j.eclinm.2024.102914_bib32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102914_bib34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"issue":"10162","key":"10.1016\/j.eclinm.2024.102914_bib35","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102914_bib37","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102914_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41416-023-02492-8","article-title":"Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN","volume":"130","author":"Shen","year":"2024","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1464-410X.2007.07261.x","article-title":"Efficacy of low-dose dexamethasone in castration-refractory prostate cancer","volume":"101","author":"Venkitaraman","year":"2008","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102914_bib40","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102914_bib41","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102914_bib44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10336","key":"10.1016\/j.eclinm.2024.102914_bib45","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102914_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/pst.2068","article-title":"Assessing the quality of studies in meta-research: review\/guidelines on the most important quality assessment tools","volume":"20","author":"Luchini","year":"2021","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102914_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102914_bib48","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jval.2021.06.003","article-title":"Investigating trends in the quality of reporting of patient-reported outcomes in oncology over time: analysis of 631 randomized controlled trials published between 2004 and 2019","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102914_bib49","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102914_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib51","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102914_bib52","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1470-2045(22)00654-4","article-title":"Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group","volume":"24","author":"Piccinin","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102914_bib53","series-title":"Framework for FDA's real-world evidence program 10903 New Hampshire ave","first-page":"37","author":"FDA US","year":"2018"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102914_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-020-00080-6","article-title":"Digital technologies for medicines: shaping a framework for success","volume":"19","author":"Cerreta","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102914_bib55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1124\/pr.120.000028","article-title":"Development of novel, value-based, digital endpoints for clinical trials: a structured approach toward fit-for-purpose validation","volume":"72","author":"Kruizinga","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.eclinm.2024.102914_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102413","article-title":"15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis","volume":"68","author":"Paravathaneni","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102914_bib57","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12885-021-08457-5","article-title":"Food and Drug Administration approvals in phase 3 Cancer clinical trials","volume":"21","author":"Abi Jaoude","year":"2021","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102914_bib58","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdy449","article-title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016","volume":"29","author":"Marandino","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102914_bib59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clgc.2019.07.007","article-title":"Quality-of-Life assessment and reporting in prostate cancer: systematic review of phase 3 trials testing anticancer drugs published between 2012 and 2018","volume":"17","author":"Marandino","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102914_bib60","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","article-title":"Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class","volume":"8","author":"Samuel","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:30:14Z","timestamp":1764624614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024004930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":60,"alternative-id":["S2589537024004930"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102914","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102914"}}